Keros Therapeutics (NASDAQ:KROS) Major Shareholder Sells $84,975,125.25 in Stock

Key Points

• Pontifax Management 4 G.P., a major shareholder of Keros Therapeutics, sold 4,787,331 shares for approximately $84.98 million on October 15th.
• Keros Therapeutics reported a quarterly earnings per share of ($0.76), surpassing analyst expectations of ($1.14) by $0.38, despite revenues being significantly below forecasts.
• Currently, Keros Therapeutics has a consensus target price of $30.00, with a mix of ratings from analysts including several "Buy," "Hold," and one "Sell."

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the firm's stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $84,975,125.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock traded up $0.09 during trading hours on Friday, hitting $13.83. 660,531 shares of the company's stock traded hands, compared to its average volume of 902,679. The stock has a market capitalization of $561.77 million, a price-to-earnings ratio of 44.61, a PEG ratio of 1.87 and a beta of 0.97. The company has a fifty day simple moving average of $15.28 and a 200-day simple moving average of $14.20. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The company's quarterly revenue was up 49002.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.25) EPS. On average, analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on KROS shares. Weiss Ratings reissued a "sell (d)" rating on shares of Keros Therapeutics in a research report on Wednesday, October 8th. HC Wainwright cut their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $30.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KROS. Corebridge Financial Inc. increased its holdings in Keros Therapeutics by 6.4% in the 1st quarter. Corebridge Financial Inc. now owns 16,212 shares of the company's stock valued at $165,000 after purchasing an additional 972 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company's stock worth $166,000 after purchasing an additional 988 shares during the period. Tower Research Capital LLC TRC grew its holdings in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after acquiring an additional 1,888 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its position in Keros Therapeutics by 29.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock worth $110,000 after purchasing an additional 1,892 shares in the last quarter. Finally, CWM LLC raised its holdings in shares of Keros Therapeutics by 45.4% in the third quarter. CWM LLC now owns 7,271 shares of the company's stock worth $115,000 after acquiring an additional 2,271 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.